H6: investigation summary: the complaint investigation for mix of extraction tubes pouches between two consecutives kits lots in the bd sars cov-2 reagents for max¿ system (ref #44500301) kit from lot 1299962 was performed by the review of manufacturing records, retention material inspection, review of customer¿s picture review and verification of complaints history.Customer reported receiving one bd sars cov-2 reagents for max¿ system kit from lot 1299962 which contained a pouch of dna extraction tubes (tx) instead of a pouch of tna extraction tubes.Review of the manufacturing process revealed that the bd sars cov-2 reagents kit lot 1299962 was produced using the fully automated process.The lot produced just before corresponds to a bd max¿ exk¿ dna kit lot 1306434, including tx from lot 1319143, also found by the customer.The retain material of bd sars cov-2 reagents from lot 1299962 was visually inspected and no anomaly was observed.The picture, provided by customer shows a bd max¿ exk¿ dna extraction tubes pouch from lot 1319143.The most likely hypothesis to explain the customer issue is an incomplete line clearance between the end of production of the bd max¿ exk¿ dna kit and the start of the bd sars cov-2 reagents for bd max¿ systems kit lot 1299962.There is no indication of mix of extraction tubes pouches between two consecutive kits based on the analysis of the complaints received on bd max products.The root cause was not identified.Bd cannot confirm the complaint based on the investigation that was performed.No corrective and preventive action (capa) was initiated at this time but improvements to the line clearance process were since made, implemented, and communicated to the operators.These improvements were made after manufacturing of bd sars cov-2 reagents for max¿ system kit lot 1299962.
|